12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

Sarepta Therapeutics, University of Western Australia deal

The university granted Sarepta exclusive, worldwide rights to IP covering exon-skipping drug candidates for Duchenne muscular dystrophy (DMD). The university is eligible to receive up to $7.1 million in upfront and milestone...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >